Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with typical Parkinson's disease according to the Gibb criteria and the Parkinson's Disease Society criteria (Daniel and Lees, 1993).~* Ideally less than 2 to 3 years since disease onset and never more than 4 years.~* Patients on dopaminergic drugs and/or L-Dopa.~* Non-fluctuating disease because otherwise the degenerative process would be well advanced, the clinical score would vary from one day to another and the imaging evaluation would be complicated by dyskinesia.~Exclusion Criteria:~* Subjects over the age of 80~* Demented subjects: MMSE score ≤ 24, Mattis score of \< 130 and DSM IV criteria~* Subjects with radiological anomalies on MRI, whether incidental or suggestive of vascular involvement or significant cortical or subcortical atrophy~* Subjects for whom MRI is contra-indicated (metal objects in the body, severe claustrophobia, pacemaker, etc.)~* Subjects undergoing brain stimulation~* Very severe rest tremor, which could induce MRI artifacts~* Subjects that have not stabilized in terms of the therapeutic regimen and who are likely to require changes in their dopamine therapy in the coming 6 months~* Hoehn and Yahr stage ≥ 3 in the Off state, indicating the need for walking assistance in the absence of treatment.~* Hypersensitivity to iron chelator drugs~* Patients at risk of or having experienced agranulocytosis~* Patients on a drug that can potentially induce agranulocytosis (clozapine, Closaril®/Leponex®)~* Patients with anemia (regardless of the latter's etiology) or a history of other hematological diseases - even an iron deficiency~* Ferritin blood level \< 100 ng/ml (100 µg/l)~* A history of hemochromatosis or known iron metabolism disorders.~* Pregnant or breastfeeding women or women not taking effective contraception~* Kidney or liver failure~* Blood coagulation disorders, antiplatelet drugs or anticoagulants~* Concomitant treatment with aluminum-based antacids (interaction)~* Concomitant treatment with vitamin C (interaction)~* Presence of other serious diseases~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- deferiprone (Type: ACTIVE_COMPARATOR): deferiprone 30 mg/kg/day
- placebo (Type: PLACEBO_COMPARATOR): placebo : 30 mg/kg/day, in 2 liquid doses

Based on this trial design, predict the completion outcome and termination type (if applicable).